Cozzolino M - Search Results

1

Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America.

Cozzolino M, Shilov E, Li Z, Fukagawa M, Al-Ghamdi SMG, Pisoni R, Bieber B, Vallabh B, Chand DH. Cozzolino M, et al. Adv Ther. 2020 Jun;37(6):2748-2762. doi: 10.1007/s12325-020-01359-1. Epub 2020 May 14. Adv Ther. 2020. PMID: 32410164 Free PMC article.

2

Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.

Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G. Cozzolino M, et al. J Nephrol. 2006 Sep-Oct;19(5):566-77. J Nephrol. 2006. PMID: 17136683 Review.

3

Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.

Cozzolino M, Galassi A, Gallieni M, Brancaccio D. Cozzolino M, et al. Curr Vasc Pharmacol. 2008 Apr;6(2):148-53. doi: 10.2174/157016108783955310. Curr Vasc Pharmacol. 2008. PMID: 18393917 Review.

4

Pathogenesis of secondary hyperparathyroidism.

Cozzolino M, Pasho S, Fallabrino G, Olivi L, Gallieni M, Brancaccio D. Cozzolino M, et al. Int J Artif Organs. 2009 Feb;32(2):75-80. doi: 10.1177/039139880903200203. Int J Artif Organs. 2009. PMID: 19363778 Free article. Review.

5

Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease.

Cozzolino M, Gallieni M, Pasho S, Fallabrino G, Ciceri P, Volpi EM, Olivi L, Brancaccio D. Cozzolino M, et al. Drugs Aging. 2009;26(6):457-68. doi: 10.2165/00002512-200926060-00002. Drugs Aging. 2009. PMID: 19591520 Review.

6

Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.

Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S. Cozzolino M, et al. Nephrol Dial Transplant. 2014 Apr;29(4):899-905. doi: 10.1093/ndt/gfu011. Epub 2014 Feb 4. Nephrol Dial Transplant. 2014. PMID: 24500308 Clinical Trial.

7

Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort.

Cozzolino M, Messa P, Brancaccio D, Cannella G, Bolasco P, Di Luca M, Costanzo AM, Paparatti Ud, Festa V, Gualberti G, Mazzaferro S; FARO Study Group. Cozzolino M, et al. Blood Purif. 2014;38(1):37-45. doi: 10.1159/000365386. Epub 2014 Sep 27. Blood Purif. 2014. PMID: 25277167 Free article.

8

Emerging drugs for secondary hyperparathyroidism.

Cozzolino M, Tomlinson J, Walsh L, Bellasi A. Cozzolino M, et al. Expert Opin Emerg Drugs. 2015 Jun;20(2):197-208. doi: 10.1517/14728214.2015.1018177. Epub 2015 Feb 23. Expert Opin Emerg Drugs. 2015. PMID: 25702624 Review.

9

Treatment Failure of Active Vitamin D Therapy in Chronic Kidney Disease: Predictive Factors.

Cozzolino M, Covic A, Martinez-Placencia B, Xynos K. Cozzolino M, et al. Am J Nephrol. 2015;42(3):228-36. doi: 10.1159/000441095. Epub 2015 Oct 7. Am J Nephrol. 2015. PMID: 26439891 Free article. Review.

10

Secondary Hyperparathyroidism in End-Stage Renal Disease: No Longer a Matter for Surgeons?

Cozzolino M, Elli F, Carugo S, Ciceri P. Cozzolino M, et al. Blood Purif. 2016;42(1):44-8. doi: 10.1159/000445204. Epub 2016 Apr 2. Blood Purif. 2016. PMID: 27035129 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

711 results

Search Page

Filters